Pfizer Completes Acquisition Of Icagen

Pfizer Inc.

announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer taxes. As a result of the acquisition, Icagen's common stock on NASDAQ will cease trading as of the opening of trading today.